Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
PLoS Med. 2023 Jan 3;20(1):e1003988. doi: 10.1371/journal.pmed.1003988. eCollection 2023 Jan. PLoS Med. 2023. PMID: 36595504 Free PMC article.